Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
about
Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgiaVaccination against herpes zoster in developed countries: state of the evidenceEstimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013.Zoster vaccination: A new opportunity for adult immunization.Compliance with herpes zoster vaccination in young and adult individuals in two regions of ItalyAssessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.Management and prevention of herpes zoster: A Canadian perspective.A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.Herpes zoster and postherpetic neuralgia surveillance using structured electronic data.Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, GreeceCost-effectiveness of vaccination against herpes zoster.Presentation and management of herpes zoster (shingles) in the geriatric population.Post-herpetic neuralgia.Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderlyHealth economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they?Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in GermanyHerpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetesComparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or olderCost-effectiveness of varicella vaccination programs: an update of the literature.Postherpetic neuralgia in the elderly.Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies.A systematic review of the cost effectiveness of herpes zoster vaccination.Vaccination in the elderly: what can be recommended?Herpes zoster vaccine: A health economic evaluation for Switzerland.Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis.National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years.COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.Pain, Itch, Quality of Life, and Costs after Herpes Zoster.Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy.Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.Immunity and the burden of herpes zoster.Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.Post-shingles neuralgia by any definition is painful, but is it PHN?Clinical and economic impact of herpes zoster vaccination in elderly in Italy.Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
P2860
Q24606799-A2C1F181-9298-4552-B5F2-92BA126F3CE9Q26862748-DB447B26-409A-4F0F-B728-5FB58C30C7B1Q30375188-D834D46E-A806-4BC3-B6DC-6046545F5A80Q33593678-DDDC898D-06C8-4438-A34E-AFB6D97C0789Q33602005-859FE40F-3AA2-4AD0-8EE8-B35FCC513148Q33657323-6A52BD43-DF77-4A7E-B083-4ACD07932D58Q33779986-A12FBD01-9A8D-47F0-935A-FECFC2C5DC0EQ33894866-3BDD626D-6E12-452C-B715-76ADA6669F3CQ34047979-D43B4D4A-B881-4E56-A8AD-E7B4D9BD09B7Q34092634-0799079C-2F40-4C9D-B378-02B3FA96ED11Q34291150-1B9D84E6-1878-4AA3-8E6A-E6440D4377C4Q34352218-84639E0A-7639-46B6-BDCF-5249D8162BDAQ34460207-8865A94E-06D3-4CAE-9E76-4C4120A0A187Q34982647-DC07F547-CF9E-452A-8F29-CA648617A57FQ35000186-A5A1DB87-F5D6-4905-BD1D-8E318CB67704Q35558544-5928322A-17FC-4014-88F7-1E23F868F2E5Q35627422-818D703E-AF8C-4E8B-9D83-1573E0043721Q35652212-450F2466-ECE8-4804-A601-B7F76DAE44ABQ35887517-6F043657-F55E-4BB4-9B2A-162EA9146256Q35887721-87FBBA43-CEDF-489B-87EF-F402B402C988Q36477832-38739F18-574C-4A89-AA62-486241531975Q37190911-6C37A7B2-299A-45DE-8565-4752F7EBA5ECQ37229923-57B917E2-FC15-47BA-AF95-63A98493DA21Q37427315-16E3047B-081B-4C2C-B8E1-59E281B989F3Q37538386-0C3475EE-E7A8-4527-9D3B-B111845DE1C3Q38038057-8E6B13D1-21DE-491B-9072-9CE975886196Q38075493-4AD3A081-E8EE-4451-A8EF-022F20C32E12Q38220158-8E7CE092-0A8E-4270-BE29-48083DC95E8DQ38798312-5C208EFB-BA0F-4DF9-BB99-6FF42B1A6871Q38811474-71D0A5A3-4420-4EB9-BAF5-2DCA1C3A6B5EQ39308910-BC2D7BDC-412C-44EE-AD3F-D1BB2A1B9426Q39394780-762F4041-289F-4189-A44F-824A22A685C4Q39406704-9C382FD4-C6F0-41AC-8EAC-9A42C79EAF31Q39750613-8A6FD01F-7010-4154-93BC-618805FA845DQ40891715-D0A932EF-65D9-4D70-BC54-316D36BEB813Q42242684-A20D601C-12E0-408E-A4DE-EBB40B20ABECQ42273664-80CFA13B-8176-4363-A664-50F7FFB3AB68Q42997215-25E1FF21-4797-42A7-A788-18E0C0E19AF3Q45937750-BE424B83-4D80-41E4-B8C3-CF0AD243B878Q46941948-A1AFCE31-1538-47FD-B42E-65579A96C5FF
P2860
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@ast
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@en
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@nl
type
label
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@ast
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@en
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@nl
prefLabel
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@ast
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@en
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@nl
P2093
P1433
P1476
Evaluation of the cost-effecti ...... etic neuralgia in older adults
@en
P2093
James M. Pellissier
Marc Brisson
Myron J. Levin
P304
P356
10.1016/J.VACCINE.2007.09.066
P407
P577
2007-11-01T00:00:00Z